Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children

Robert L Findling, Joseph Biederman, Timothy E. Wilens, Thomas J. Spencer, James J. McGough, Frank A. Lopez, Simon J. Tulloch

Research output: Contribution to journalArticle

Abstract

Objective: To assess the short- and long-term cardiovascular effects of once-daily treatment with a mixed amphetamine salts extended-release formulation (MAS XR; Adderall XR®) in children age 6 to 12 years with attention-deficit/hyperactivity disorder (ADHD). Study design: Short-term cardiovascular effects were assessed during a 4-week, double-blind, randomized, placebo-controlled, forced-dose-titration study of once-daily 10, 20, and 30 mg MAS XR (n = 580). Long-term cardiovascular effects were assessed in 568 subjects during a 2-year, open-label extension study of MAS XR (10 to 30 mg/day). Resting sitting blood pressure and pulse were measured at baseline and weekly during the short-term study, then monthly during long-term treatment. Results: Changes in blood pressure, pulse, and QT interval corrected by Bazett's formula (QTcB) in children receiving MAS XR were not statistically significantly different than those changes seen in children receiving placebo during short-term treatment. Mean increases in blood pressure after 2 years of MAS XR treatment (systolic, 3.5 mm Hg; diastolic, 2.6 mm Hg) and pulse (3.4 bpm) were clinically insignificant, and there was no apparent dose-response relationship. Conclusions: Cardiovascular effects of short- and long-term MAS XR were minimal during short- and long-term MAS XR treatment at doses of ≤ 30 mg/day in otherwise healthy children.

Original languageEnglish (US)
Pages (from-to)348-354
Number of pages7
JournalJournal of Pediatrics
Volume147
Issue number3
DOIs
StatePublished - Sep 2005
Externally publishedYes

Fingerprint

Amphetamine
Salts
Blood Pressure
Placebos
Therapeutics
Attention Deficit Disorder with Hyperactivity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Findling, R. L., Biederman, J., Wilens, T. E., Spencer, T. J., McGough, J. J., Lopez, F. A., & Tulloch, S. J. (2005). Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. Journal of Pediatrics, 147(3), 348-354. https://doi.org/10.1016/j.jpeds.2005.03.014

Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. / Findling, Robert L; Biederman, Joseph; Wilens, Timothy E.; Spencer, Thomas J.; McGough, James J.; Lopez, Frank A.; Tulloch, Simon J.

In: Journal of Pediatrics, Vol. 147, No. 3, 09.2005, p. 348-354.

Research output: Contribution to journalArticle

Findling, RL, Biederman, J, Wilens, TE, Spencer, TJ, McGough, JJ, Lopez, FA & Tulloch, SJ 2005, 'Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children', Journal of Pediatrics, vol. 147, no. 3, pp. 348-354. https://doi.org/10.1016/j.jpeds.2005.03.014
Findling, Robert L ; Biederman, Joseph ; Wilens, Timothy E. ; Spencer, Thomas J. ; McGough, James J. ; Lopez, Frank A. ; Tulloch, Simon J. / Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. In: Journal of Pediatrics. 2005 ; Vol. 147, No. 3. pp. 348-354.
@article{b39f00732569470f9b898d0f10a99fdd,
title = "Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children",
abstract = "Objective: To assess the short- and long-term cardiovascular effects of once-daily treatment with a mixed amphetamine salts extended-release formulation (MAS XR; Adderall XR{\circledR}) in children age 6 to 12 years with attention-deficit/hyperactivity disorder (ADHD). Study design: Short-term cardiovascular effects were assessed during a 4-week, double-blind, randomized, placebo-controlled, forced-dose-titration study of once-daily 10, 20, and 30 mg MAS XR (n = 580). Long-term cardiovascular effects were assessed in 568 subjects during a 2-year, open-label extension study of MAS XR (10 to 30 mg/day). Resting sitting blood pressure and pulse were measured at baseline and weekly during the short-term study, then monthly during long-term treatment. Results: Changes in blood pressure, pulse, and QT interval corrected by Bazett's formula (QTcB) in children receiving MAS XR were not statistically significantly different than those changes seen in children receiving placebo during short-term treatment. Mean increases in blood pressure after 2 years of MAS XR treatment (systolic, 3.5 mm Hg; diastolic, 2.6 mm Hg) and pulse (3.4 bpm) were clinically insignificant, and there was no apparent dose-response relationship. Conclusions: Cardiovascular effects of short- and long-term MAS XR were minimal during short- and long-term MAS XR treatment at doses of ≤ 30 mg/day in otherwise healthy children.",
author = "Findling, {Robert L} and Joseph Biederman and Wilens, {Timothy E.} and Spencer, {Thomas J.} and McGough, {James J.} and Lopez, {Frank A.} and Tulloch, {Simon J.}",
year = "2005",
month = "9",
doi = "10.1016/j.jpeds.2005.03.014",
language = "English (US)",
volume = "147",
pages = "348--354",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children

AU - Findling, Robert L

AU - Biederman, Joseph

AU - Wilens, Timothy E.

AU - Spencer, Thomas J.

AU - McGough, James J.

AU - Lopez, Frank A.

AU - Tulloch, Simon J.

PY - 2005/9

Y1 - 2005/9

N2 - Objective: To assess the short- and long-term cardiovascular effects of once-daily treatment with a mixed amphetamine salts extended-release formulation (MAS XR; Adderall XR®) in children age 6 to 12 years with attention-deficit/hyperactivity disorder (ADHD). Study design: Short-term cardiovascular effects were assessed during a 4-week, double-blind, randomized, placebo-controlled, forced-dose-titration study of once-daily 10, 20, and 30 mg MAS XR (n = 580). Long-term cardiovascular effects were assessed in 568 subjects during a 2-year, open-label extension study of MAS XR (10 to 30 mg/day). Resting sitting blood pressure and pulse were measured at baseline and weekly during the short-term study, then monthly during long-term treatment. Results: Changes in blood pressure, pulse, and QT interval corrected by Bazett's formula (QTcB) in children receiving MAS XR were not statistically significantly different than those changes seen in children receiving placebo during short-term treatment. Mean increases in blood pressure after 2 years of MAS XR treatment (systolic, 3.5 mm Hg; diastolic, 2.6 mm Hg) and pulse (3.4 bpm) were clinically insignificant, and there was no apparent dose-response relationship. Conclusions: Cardiovascular effects of short- and long-term MAS XR were minimal during short- and long-term MAS XR treatment at doses of ≤ 30 mg/day in otherwise healthy children.

AB - Objective: To assess the short- and long-term cardiovascular effects of once-daily treatment with a mixed amphetamine salts extended-release formulation (MAS XR; Adderall XR®) in children age 6 to 12 years with attention-deficit/hyperactivity disorder (ADHD). Study design: Short-term cardiovascular effects were assessed during a 4-week, double-blind, randomized, placebo-controlled, forced-dose-titration study of once-daily 10, 20, and 30 mg MAS XR (n = 580). Long-term cardiovascular effects were assessed in 568 subjects during a 2-year, open-label extension study of MAS XR (10 to 30 mg/day). Resting sitting blood pressure and pulse were measured at baseline and weekly during the short-term study, then monthly during long-term treatment. Results: Changes in blood pressure, pulse, and QT interval corrected by Bazett's formula (QTcB) in children receiving MAS XR were not statistically significantly different than those changes seen in children receiving placebo during short-term treatment. Mean increases in blood pressure after 2 years of MAS XR treatment (systolic, 3.5 mm Hg; diastolic, 2.6 mm Hg) and pulse (3.4 bpm) were clinically insignificant, and there was no apparent dose-response relationship. Conclusions: Cardiovascular effects of short- and long-term MAS XR were minimal during short- and long-term MAS XR treatment at doses of ≤ 30 mg/day in otherwise healthy children.

UR - http://www.scopus.com/inward/record.url?scp=25144476583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144476583&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2005.03.014

DO - 10.1016/j.jpeds.2005.03.014

M3 - Article

VL - 147

SP - 348

EP - 354

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 3

ER -